Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06164873
PHASE3

A Study of IBI362 9 mg in Chinese Adults With Obesity

Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

View on ClinicalTrials.gov

Summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical study evaluating the efficacy and safety of IBI362 9 mg in obese subjects. Subjects will be randomly assigned to IBI362 9 mg and placebo groups. All study treatment will be administered once-weekly and subcutaneously. The entire trial cycle includes a 2-week screening period, a 60-week double-blind treatment period, and a 12-week drug withdrawal follow-up period after the end of treatment.

Official title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of IBI362 9 mg in Chinese Participants With Obesity (GLORY-2)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

462

Start Date

2023-12-27

Completion Date

2025-09-19

Last Updated

2024-08-27

Healthy Volunteers

No

Conditions

Interventions

DRUG

IBI362

Once-weekly injections of gradually increased doses of IBI362

DRUG

Placebo

Once-weekly injections of volume-matched placebo

Locations (1)

Peking University People's Hospital

Beijing, Beijing Municipality, China